nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.075	0.137	CbGbCtD
Iloperidone—CYP3A7—Paclitaxel—ovarian cancer	0.075	0.137	CbGbCtD
Iloperidone—CYP3A5—Paclitaxel—ovarian cancer	0.0562	0.103	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0542	0.0989	CbGbCtD
Iloperidone—CYP3A7—Docetaxel—ovarian cancer	0.0542	0.0989	CbGbCtD
Iloperidone—CYP2D6—Vinorelbine—ovarian cancer	0.0491	0.0896	CbGbCtD
Iloperidone—CYP3A4—Topotecan—ovarian cancer	0.0443	0.0808	CbGbCtD
Iloperidone—CYP3A5—Docetaxel—ovarian cancer	0.0407	0.0742	CbGbCtD
Iloperidone—CYP3A4—Vinorelbine—ovarian cancer	0.0312	0.0569	CbGbCtD
Iloperidone—CYP3A4—Paclitaxel—ovarian cancer	0.0219	0.04	CbGbCtD
Iloperidone—CYP2D6—Doxorubicin—ovarian cancer	0.0186	0.0339	CbGbCtD
Iloperidone—CYP3A4—Docetaxel—ovarian cancer	0.0159	0.0289	CbGbCtD
Iloperidone—CYP3A4—Doxorubicin—ovarian cancer	0.0118	0.0216	CbGbCtD
Iloperidone—HTR7—vein—ovarian cancer	0.0109	0.117	CbGeAlD
Iloperidone—Gefitinib—CHEK2—ovarian cancer	0.00689	0.588	CrCbGaD
Iloperidone—HTR2A—vein—ovarian cancer	0.00677	0.0731	CbGeAlD
Iloperidone—DRD4—testis—ovarian cancer	0.00319	0.0345	CbGeAlD
Iloperidone—Gefitinib—EGFR—ovarian cancer	0.00275	0.235	CrCbGaD
Iloperidone—SIGMAR1—myometrium—ovarian cancer	0.0025	0.027	CbGeAlD
Iloperidone—ADRA2C—myometrium—ovarian cancer	0.00196	0.0212	CbGeAlD
Iloperidone—SIGMAR1—uterine cervix—ovarian cancer	0.00195	0.021	CbGeAlD
Iloperidone—SIGMAR1—decidua—ovarian cancer	0.00185	0.02	CbGeAlD
Iloperidone—SIGMAR1—endometrium—ovarian cancer	0.00176	0.019	CbGeAlD
Iloperidone—HTR7—epithelium—ovarian cancer	0.00168	0.0181	CbGeAlD
Iloperidone—SIGMAR1—uterus—ovarian cancer	0.00162	0.0175	CbGeAlD
Iloperidone—ADRA1A—epithelium—ovarian cancer	0.00162	0.0175	CbGeAlD
Iloperidone—HRH1—myometrium—ovarian cancer	0.00159	0.0172	CbGeAlD
Iloperidone—ADRA2A—myometrium—ovarian cancer	0.00157	0.0169	CbGeAlD
Iloperidone—HTR1D—female reproductive system—ovarian cancer	0.00156	0.0169	CbGeAlD
Iloperidone—HTR2C—female reproductive system—ovarian cancer	0.00155	0.0167	CbGeAlD
Iloperidone—ADRA2C—uterine cervix—ovarian cancer	0.00153	0.0165	CbGeAlD
Iloperidone—ADRA2C—decidua—ovarian cancer	0.00146	0.0157	CbGeAlD
Iloperidone—HTR7—gonad—ovarian cancer	0.00139	0.0151	CbGeAlD
Iloperidone—ADRA2C—endometrium—ovarian cancer	0.00138	0.0149	CbGeAlD
Iloperidone—SIGMAR1—bone marrow—ovarian cancer	0.00138	0.0149	CbGeAlD
Iloperidone—SIGMAR1—female gonad—ovarian cancer	0.00133	0.0143	CbGeAlD
Iloperidone—SIGMAR1—vagina—ovarian cancer	0.00132	0.0142	CbGeAlD
Iloperidone—HTR2A—embryo—ovarian cancer	0.00128	0.0138	CbGeAlD
Iloperidone—CYP3A5—uterine cervix—ovarian cancer	0.00128	0.0138	CbGeAlD
Iloperidone—ADRA2C—uterus—ovarian cancer	0.00127	0.0137	CbGeAlD
Iloperidone—HRH1—epithelium—ovarian cancer	0.00125	0.0135	CbGeAlD
Iloperidone—HTR7—female reproductive system—ovarian cancer	0.00125	0.0134	CbGeAlD
Iloperidone—HRH1—uterine cervix—ovarian cancer	0.00124	0.0134	CbGeAlD
Iloperidone—Risperidone—ABCB1—ovarian cancer	0.00124	0.106	CrCbGaD
Iloperidone—ADRA2A—uterine cervix—ovarian cancer	0.00122	0.0132	CbGeAlD
Iloperidone—HRH1—decidua—ovarian cancer	0.00118	0.0128	CbGeAlD
Iloperidone—SIGMAR1—testis—ovarian cancer	0.00118	0.0127	CbGeAlD
Iloperidone—ADRA2A—decidua—ovarian cancer	0.00116	0.0125	CbGeAlD
Iloperidone—HRH1—endometrium—ovarian cancer	0.00112	0.0121	CbGeAlD
Iloperidone—ADRA2A—endometrium—ovarian cancer	0.0011	0.0119	CbGeAlD
Iloperidone—HTR2A—epithelium—ovarian cancer	0.00105	0.0113	CbGeAlD
Iloperidone—ADRA2C—female gonad—ovarian cancer	0.00104	0.0112	CbGeAlD
Iloperidone—ADRA2C—vagina—ovarian cancer	0.00104	0.0112	CbGeAlD
Iloperidone—ADRA2A—gonad—ovarian cancer	0.00102	0.011	CbGeAlD
Iloperidone—ADRA2A—uterus—ovarian cancer	0.00102	0.011	CbGeAlD
Iloperidone—HTR7—testis—ovarian cancer	0.001	0.0109	CbGeAlD
Iloperidone—DRD2—testis—ovarian cancer	0.00095	0.0103	CbGeAlD
Iloperidone—HRH1—female reproductive system—ovarian cancer	0.00093	0.01	CbGeAlD
Iloperidone—ADRA2C—testis—ovarian cancer	0.000924	0.00997	CbGeAlD
Iloperidone—ADRA2A—female reproductive system—ovarian cancer	0.000913	0.00986	CbGeAlD
Iloperidone—CYP2E1—female reproductive system—ovarian cancer	0.000893	0.00965	CbGeAlD
Iloperidone—CYP3A5—female gonad—ovarian cancer	0.000872	0.00941	CbGeAlD
Iloperidone—HTR2A—gonad—ovarian cancer	0.000869	0.00939	CbGeAlD
Iloperidone—CYP3A5—vagina—ovarian cancer	0.000866	0.00936	CbGeAlD
Iloperidone—SIGMAR1—lymph node—ovarian cancer	0.000853	0.00921	CbGeAlD
Iloperidone—HRH1—female gonad—ovarian cancer	0.000846	0.00914	CbGeAlD
Iloperidone—HRH1—vagina—ovarian cancer	0.000841	0.00908	CbGeAlD
Iloperidone—Gefitinib—ABCB1—ovarian cancer	0.000838	0.0714	CrCbGaD
Iloperidone—ADRA2A—female gonad—ovarian cancer	0.000831	0.00897	CbGeAlD
Iloperidone—ADRA2A—vagina—ovarian cancer	0.000826	0.00892	CbGeAlD
Iloperidone—HTR2A—female reproductive system—ovarian cancer	0.000776	0.00839	CbGeAlD
Iloperidone—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000772	0.00239	CcSEcCtD
Iloperidone—Fatigue—Melphalan—ovarian cancer	0.000771	0.00239	CcSEcCtD
Iloperidone—Nervous system disorder—Vinorelbine—ovarian cancer	0.000766	0.00237	CcSEcCtD
Iloperidone—Tachycardia—Vinorelbine—ovarian cancer	0.000763	0.00236	CcSEcCtD
Iloperidone—Mouth ulceration—Epirubicin—ovarian cancer	0.000762	0.00236	CcSEcCtD
Iloperidone—Salivary hypersecretion—Doxorubicin—ovarian cancer	0.000757	0.00234	CcSEcCtD
Iloperidone—Feeling abnormal—Topotecan—ovarian cancer	0.000753	0.00233	CcSEcCtD
Iloperidone—HRH1—testis—ovarian cancer	0.00075	0.0081	CbGeAlD
Iloperidone—Fluid retention—Doxorubicin—ovarian cancer	0.00074	0.00229	CcSEcCtD
Iloperidone—ADRA2A—testis—ovarian cancer	0.000737	0.00796	CbGeAlD
Iloperidone—Asthenia—Chlorambucil—ovarian cancer	0.000736	0.00228	CcSEcCtD
Iloperidone—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000731	0.00226	CcSEcCtD
Iloperidone—Hypotension—Vinorelbine—ovarian cancer	0.00073	0.00226	CcSEcCtD
Iloperidone—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000727	0.00225	CcSEcCtD
Iloperidone—Urethral disorder—Paclitaxel—ovarian cancer	0.000725	0.00225	CcSEcCtD
Iloperidone—Body temperature increased—Topotecan—ovarian cancer	0.000722	0.00224	CcSEcCtD
Iloperidone—CYP2E1—testis—ovarian cancer	0.000721	0.00779	CbGeAlD
Iloperidone—Dry eye—Doxorubicin—ovarian cancer	0.00072	0.00223	CcSEcCtD
Iloperidone—CYP3A4—female reproductive system—ovarian cancer	0.000719	0.00776	CbGeAlD
Iloperidone—Weight increased—Docetaxel—ovarian cancer	0.000713	0.00221	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000712	0.00221	CcSEcCtD
Iloperidone—Weight decreased—Docetaxel—ovarian cancer	0.000709	0.0022	CcSEcCtD
Iloperidone—CYP2D6—female reproductive system—ovarian cancer	0.000707	0.00764	CbGeAlD
Iloperidone—Mouth ulceration—Doxorubicin—ovarian cancer	0.000705	0.00218	CcSEcCtD
Iloperidone—HTR2A—vagina—ovarian cancer	0.000702	0.00758	CbGeAlD
Iloperidone—Diarrhoea—Chlorambucil—ovarian cancer	0.000702	0.00217	CcSEcCtD
Iloperidone—Paraesthesia—Vinorelbine—ovarian cancer	0.000702	0.00217	CcSEcCtD
Iloperidone—Dyspnoea—Vinorelbine—ovarian cancer	0.000697	0.00216	CcSEcCtD
Iloperidone—Eye disorder—Paclitaxel—ovarian cancer	0.000691	0.00214	CcSEcCtD
Iloperidone—Tinnitus—Paclitaxel—ovarian cancer	0.00069	0.00214	CcSEcCtD
Iloperidone—Cardiac disorder—Paclitaxel—ovarian cancer	0.000687	0.00213	CcSEcCtD
Iloperidone—Stomatitis—Docetaxel—ovarian cancer	0.000681	0.00211	CcSEcCtD
Iloperidone—Conjunctivitis—Docetaxel—ovarian cancer	0.000679	0.0021	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000675	0.00209	CcSEcCtD
Iloperidone—Fatigue—Vinorelbine—ovarian cancer	0.000674	0.00209	CcSEcCtD
Iloperidone—Angiopathy—Paclitaxel—ovarian cancer	0.000671	0.00208	CcSEcCtD
Iloperidone—ADRA2C—lymph node—ovarian cancer	0.000669	0.00723	CbGeAlD
Iloperidone—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000667	0.00207	CcSEcCtD
Iloperidone—Renal failure acute—Epirubicin—ovarian cancer	0.000662	0.00205	CcSEcCtD
Iloperidone—Arrhythmia—Paclitaxel—ovarian cancer	0.000661	0.00205	CcSEcCtD
Iloperidone—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000661	0.00205	CcSEcCtD
Iloperidone—Epistaxis—Docetaxel—ovarian cancer	0.000659	0.00204	CcSEcCtD
Iloperidone—Asthenia—Topotecan—ovarian cancer	0.000656	0.00203	CcSEcCtD
Iloperidone—Increased appetite—Epirubicin—ovarian cancer	0.000651	0.00202	CcSEcCtD
Iloperidone—Mental disorder—Paclitaxel—ovarian cancer	0.000648	0.00201	CcSEcCtD
Iloperidone—Malnutrition—Paclitaxel—ovarian cancer	0.000644	0.002	CcSEcCtD
Iloperidone—Feeling abnormal—Vinorelbine—ovarian cancer	0.000644	0.00199	CcSEcCtD
Iloperidone—CYP2D6—female gonad—ovarian cancer	0.000644	0.00695	CbGeAlD
Iloperidone—Asthenia—Melphalan—ovarian cancer	0.000642	0.00199	CcSEcCtD
Iloperidone—HTR2A—testis—ovarian cancer	0.000627	0.00677	CbGeAlD
Iloperidone—Cardiac failure—Epirubicin—ovarian cancer	0.000627	0.00194	CcSEcCtD
Iloperidone—Diarrhoea—Topotecan—ovarian cancer	0.000625	0.00194	CcSEcCtD
Iloperidone—Lethargy—Epirubicin—ovarian cancer	0.000624	0.00193	CcSEcCtD
Iloperidone—Urinary tract disorder—Docetaxel—ovarian cancer	0.000619	0.00192	CcSEcCtD
Iloperidone—Muscle spasms—Paclitaxel—ovarian cancer	0.000619	0.00192	CcSEcCtD
Iloperidone—Body temperature increased—Vinorelbine—ovarian cancer	0.000618	0.00191	CcSEcCtD
Iloperidone—Connective tissue disorder—Docetaxel—ovarian cancer	0.000616	0.00191	CcSEcCtD
Iloperidone—Urethral disorder—Docetaxel—ovarian cancer	0.000615	0.0019	CcSEcCtD
Iloperidone—Renal failure acute—Doxorubicin—ovarian cancer	0.000613	0.0019	CcSEcCtD
Iloperidone—Diarrhoea—Melphalan—ovarian cancer	0.000612	0.0019	CcSEcCtD
Iloperidone—Nausea—Chlorambucil—ovarian cancer	0.00061	0.00189	CcSEcCtD
Iloperidone—Vision blurred—Paclitaxel—ovarian cancer	0.000607	0.00188	CcSEcCtD
Iloperidone—Dizziness—Topotecan—ovarian cancer	0.000604	0.00187	CcSEcCtD
Iloperidone—Tremor—Paclitaxel—ovarian cancer	0.000603	0.00187	CcSEcCtD
Iloperidone—Increased appetite—Doxorubicin—ovarian cancer	0.000602	0.00187	CcSEcCtD
Iloperidone—Affect lability—Epirubicin—ovarian cancer	0.000602	0.00186	CcSEcCtD
Iloperidone—Anaemia—Paclitaxel—ovarian cancer	0.000595	0.00184	CcSEcCtD
Iloperidone—Agitation—Paclitaxel—ovarian cancer	0.000592	0.00183	CcSEcCtD
Iloperidone—Eye disorder—Docetaxel—ovarian cancer	0.000586	0.00182	CcSEcCtD
Iloperidone—Cardiac disorder—Docetaxel—ovarian cancer	0.000582	0.0018	CcSEcCtD
Iloperidone—Cardiac failure—Doxorubicin—ovarian cancer	0.00058	0.0018	CcSEcCtD
Iloperidone—Mood swings—Epirubicin—ovarian cancer	0.000579	0.00179	CcSEcCtD
Iloperidone—Vertigo—Paclitaxel—ovarian cancer	0.000579	0.00179	CcSEcCtD
Iloperidone—Lethargy—Doxorubicin—ovarian cancer	0.000577	0.00179	CcSEcCtD
Iloperidone—Leukopenia—Paclitaxel—ovarian cancer	0.000577	0.00179	CcSEcCtD
Iloperidone—Rash—Topotecan—ovarian cancer	0.000576	0.00178	CcSEcCtD
Iloperidone—Dermatitis—Topotecan—ovarian cancer	0.000576	0.00178	CcSEcCtD
Iloperidone—CYP2D6—testis—ovarian cancer	0.000571	0.00617	CbGeAlD
Iloperidone—Palpitations—Paclitaxel—ovarian cancer	0.000569	0.00176	CcSEcCtD
Iloperidone—Angiopathy—Docetaxel—ovarian cancer	0.000569	0.00176	CcSEcCtD
Iloperidone—Dehydration—Epirubicin—ovarian cancer	0.000569	0.00176	CcSEcCtD
Iloperidone—Mediastinal disorder—Docetaxel—ovarian cancer	0.000565	0.00175	CcSEcCtD
Iloperidone—Rash—Melphalan—ovarian cancer	0.000564	0.00175	CcSEcCtD
Iloperidone—Dermatitis—Melphalan—ovarian cancer	0.000564	0.00175	CcSEcCtD
Iloperidone—Asthenia—Vinorelbine—ovarian cancer	0.000561	0.00174	CcSEcCtD
Iloperidone—Arrhythmia—Docetaxel—ovarian cancer	0.00056	0.00174	CcSEcCtD
Iloperidone—Orthostatic hypotension—Epirubicin—ovarian cancer	0.000558	0.00173	CcSEcCtD
Iloperidone—Affect lability—Doxorubicin—ovarian cancer	0.000557	0.00172	CcSEcCtD
Iloperidone—Hypokalaemia—Epirubicin—ovarian cancer	0.000557	0.00172	CcSEcCtD
Iloperidone—Breast disorder—Epirubicin—ovarian cancer	0.000553	0.00171	CcSEcCtD
Iloperidone—Mental disorder—Docetaxel—ovarian cancer	0.000549	0.0017	CcSEcCtD
Iloperidone—Arthralgia—Paclitaxel—ovarian cancer	0.000548	0.0017	CcSEcCtD
Iloperidone—Myalgia—Paclitaxel—ovarian cancer	0.000548	0.0017	CcSEcCtD
Iloperidone—Nasopharyngitis—Epirubicin—ovarian cancer	0.000547	0.00169	CcSEcCtD
Iloperidone—Malnutrition—Docetaxel—ovarian cancer	0.000546	0.00169	CcSEcCtD
Iloperidone—HRH1—lymph node—ovarian cancer	0.000544	0.00587	CbGeAlD
Iloperidone—Nausea—Topotecan—ovarian cancer	0.000543	0.00168	CcSEcCtD
Iloperidone—Gastritis—Epirubicin—ovarian cancer	0.000541	0.00168	CcSEcCtD
Iloperidone—Dry mouth—Paclitaxel—ovarian cancer	0.000536	0.00166	CcSEcCtD
Iloperidone—Mood swings—Doxorubicin—ovarian cancer	0.000536	0.00166	CcSEcCtD
Iloperidone—Diarrhoea—Vinorelbine—ovarian cancer	0.000535	0.00166	CcSEcCtD
Iloperidone—ADRA2A—lymph node—ovarian cancer	0.000534	0.00577	CbGeAlD
Iloperidone—Nausea—Melphalan—ovarian cancer	0.000531	0.00165	CcSEcCtD
Iloperidone—Confusional state—Paclitaxel—ovarian cancer	0.00053	0.00164	CcSEcCtD
Iloperidone—Asthma—Epirubicin—ovarian cancer	0.000529	0.00164	CcSEcCtD
Iloperidone—Dehydration—Doxorubicin—ovarian cancer	0.000526	0.00163	CcSEcCtD
Iloperidone—Oedema—Paclitaxel—ovarian cancer	0.000526	0.00163	CcSEcCtD
Iloperidone—Muscle spasms—Docetaxel—ovarian cancer	0.000525	0.00163	CcSEcCtD
Iloperidone—Infection—Paclitaxel—ovarian cancer	0.000522	0.00162	CcSEcCtD
Iloperidone—Dizziness—Vinorelbine—ovarian cancer	0.000517	0.0016	CcSEcCtD
Iloperidone—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000517	0.0016	CcSEcCtD
Iloperidone—Nervous system disorder—Paclitaxel—ovarian cancer	0.000516	0.0016	CcSEcCtD
Iloperidone—Hypokalaemia—Doxorubicin—ovarian cancer	0.000515	0.00159	CcSEcCtD
Iloperidone—Tachycardia—Paclitaxel—ovarian cancer	0.000513	0.00159	CcSEcCtD
Iloperidone—Breast disorder—Doxorubicin—ovarian cancer	0.000511	0.00158	CcSEcCtD
Iloperidone—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000506	0.00157	CcSEcCtD
Iloperidone—Anaemia—Docetaxel—ovarian cancer	0.000505	0.00156	CcSEcCtD
Iloperidone—Gastritis—Doxorubicin—ovarian cancer	0.000501	0.00155	CcSEcCtD
Iloperidone—Dysuria—Epirubicin—ovarian cancer	0.000494	0.00153	CcSEcCtD
Iloperidone—Rash—Vinorelbine—ovarian cancer	0.000493	0.00153	CcSEcCtD
Iloperidone—Dermatitis—Vinorelbine—ovarian cancer	0.000492	0.00152	CcSEcCtD
Iloperidone—Hypotension—Paclitaxel—ovarian cancer	0.000491	0.00152	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000491	0.00152	CcSEcCtD
Iloperidone—Asthma—Doxorubicin—ovarian cancer	0.000489	0.00151	CcSEcCtD
Iloperidone—Leukopenia—Docetaxel—ovarian cancer	0.000489	0.00151	CcSEcCtD
Iloperidone—Pollakiuria—Epirubicin—ovarian cancer	0.000488	0.00151	CcSEcCtD
Iloperidone—Palpitations—Docetaxel—ovarian cancer	0.000482	0.00149	CcSEcCtD
Iloperidone—Weight increased—Epirubicin—ovarian cancer	0.000481	0.00149	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000479	0.00148	CcSEcCtD
Iloperidone—Weight decreased—Epirubicin—ovarian cancer	0.000478	0.00148	CcSEcCtD
Iloperidone—Paraesthesia—Paclitaxel—ovarian cancer	0.000472	0.00146	CcSEcCtD
Iloperidone—Dyspnoea—Paclitaxel—ovarian cancer	0.000469	0.00145	CcSEcCtD
Iloperidone—Somnolence—Paclitaxel—ovarian cancer	0.000467	0.00145	CcSEcCtD
Iloperidone—Arthralgia—Docetaxel—ovarian cancer	0.000465	0.00144	CcSEcCtD
Iloperidone—Myalgia—Docetaxel—ovarian cancer	0.000465	0.00144	CcSEcCtD
Iloperidone—Nausea—Vinorelbine—ovarian cancer	0.000464	0.00144	CcSEcCtD
Iloperidone—Stomatitis—Epirubicin—ovarian cancer	0.000459	0.00142	CcSEcCtD
Iloperidone—Conjunctivitis—Epirubicin—ovarian cancer	0.000458	0.00142	CcSEcCtD
Iloperidone—Dysuria—Doxorubicin—ovarian cancer	0.000457	0.00142	CcSEcCtD
Iloperidone—Dry mouth—Docetaxel—ovarian cancer	0.000455	0.00141	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000454	0.00141	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000454	0.00141	CcSEcCtD
Iloperidone—Fatigue—Paclitaxel—ovarian cancer	0.000453	0.0014	CcSEcCtD
Iloperidone—Pollakiuria—Doxorubicin—ovarian cancer	0.000452	0.0014	CcSEcCtD
Iloperidone—Confusional state—Docetaxel—ovarian cancer	0.000449	0.00139	CcSEcCtD
Iloperidone—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000446	0.00138	CcSEcCtD
Iloperidone—Oedema—Docetaxel—ovarian cancer	0.000446	0.00138	CcSEcCtD
Iloperidone—Weight increased—Doxorubicin—ovarian cancer	0.000445	0.00138	CcSEcCtD
Iloperidone—Epistaxis—Epirubicin—ovarian cancer	0.000444	0.00138	CcSEcCtD
Iloperidone—Infection—Docetaxel—ovarian cancer	0.000443	0.00137	CcSEcCtD
Iloperidone—Weight decreased—Doxorubicin—ovarian cancer	0.000442	0.00137	CcSEcCtD
Iloperidone—Nervous system disorder—Docetaxel—ovarian cancer	0.000437	0.00135	CcSEcCtD
Iloperidone—Tachycardia—Docetaxel—ovarian cancer	0.000435	0.00135	CcSEcCtD
Iloperidone—Feeling abnormal—Paclitaxel—ovarian cancer	0.000433	0.00134	CcSEcCtD
Iloperidone—Stomatitis—Doxorubicin—ovarian cancer	0.000425	0.00132	CcSEcCtD
Iloperidone—Conjunctivitis—Doxorubicin—ovarian cancer	0.000424	0.00131	CcSEcCtD
Iloperidone—Urinary tract disorder—Epirubicin—ovarian cancer	0.000418	0.00129	CcSEcCtD
Iloperidone—Hypotension—Docetaxel—ovarian cancer	0.000416	0.00129	CcSEcCtD
Iloperidone—Connective tissue disorder—Epirubicin—ovarian cancer	0.000416	0.00129	CcSEcCtD
Iloperidone—Body temperature increased—Paclitaxel—ovarian cancer	0.000416	0.00129	CcSEcCtD
Iloperidone—Urethral disorder—Epirubicin—ovarian cancer	0.000415	0.00128	CcSEcCtD
Iloperidone—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000412	0.00128	CcSEcCtD
Iloperidone—Epistaxis—Doxorubicin—ovarian cancer	0.000411	0.00127	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000406	0.00126	CcSEcCtD
Iloperidone—Paraesthesia—Docetaxel—ovarian cancer	0.0004	0.00124	CcSEcCtD
Iloperidone—Dyspnoea—Docetaxel—ovarian cancer	0.000397	0.00123	CcSEcCtD
Iloperidone—Somnolence—Docetaxel—ovarian cancer	0.000396	0.00123	CcSEcCtD
Iloperidone—Eye disorder—Epirubicin—ovarian cancer	0.000395	0.00122	CcSEcCtD
Iloperidone—Tinnitus—Epirubicin—ovarian cancer	0.000394	0.00122	CcSEcCtD
Iloperidone—Cardiac disorder—Epirubicin—ovarian cancer	0.000393	0.00122	CcSEcCtD
Iloperidone—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000387	0.0012	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000385	0.00119	CcSEcCtD
Iloperidone—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000385	0.00119	CcSEcCtD
Iloperidone—Fatigue—Docetaxel—ovarian cancer	0.000384	0.00119	CcSEcCtD
Iloperidone—Angiopathy—Epirubicin—ovarian cancer	0.000384	0.00119	CcSEcCtD
Iloperidone—Urethral disorder—Doxorubicin—ovarian cancer	0.000384	0.00119	CcSEcCtD
Iloperidone—Mediastinal disorder—Epirubicin—ovarian cancer	0.000381	0.00118	CcSEcCtD
Iloperidone—Arrhythmia—Epirubicin—ovarian cancer	0.000378	0.00117	CcSEcCtD
Iloperidone—Asthenia—Paclitaxel—ovarian cancer	0.000377	0.00117	CcSEcCtD
Iloperidone—Mental disorder—Epirubicin—ovarian cancer	0.000371	0.00115	CcSEcCtD
Iloperidone—Malnutrition—Epirubicin—ovarian cancer	0.000368	0.00114	CcSEcCtD
Iloperidone—Feeling abnormal—Docetaxel—ovarian cancer	0.000367	0.00114	CcSEcCtD
Iloperidone—Eye disorder—Doxorubicin—ovarian cancer	0.000366	0.00113	CcSEcCtD
Iloperidone—Tinnitus—Doxorubicin—ovarian cancer	0.000365	0.00113	CcSEcCtD
Iloperidone—Cardiac disorder—Doxorubicin—ovarian cancer	0.000363	0.00113	CcSEcCtD
Iloperidone—Diarrhoea—Paclitaxel—ovarian cancer	0.00036	0.00111	CcSEcCtD
Iloperidone—Angiopathy—Doxorubicin—ovarian cancer	0.000355	0.0011	CcSEcCtD
Iloperidone—Muscle spasms—Epirubicin—ovarian cancer	0.000354	0.0011	CcSEcCtD
Iloperidone—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000353	0.00109	CcSEcCtD
Iloperidone—Body temperature increased—Docetaxel—ovarian cancer	0.000352	0.00109	CcSEcCtD
Iloperidone—Arrhythmia—Doxorubicin—ovarian cancer	0.00035	0.00108	CcSEcCtD
Iloperidone—Dizziness—Paclitaxel—ovarian cancer	0.000348	0.00108	CcSEcCtD
Iloperidone—Vision blurred—Epirubicin—ovarian cancer	0.000347	0.00107	CcSEcCtD
Iloperidone—Mental disorder—Doxorubicin—ovarian cancer	0.000343	0.00106	CcSEcCtD
Iloperidone—Malnutrition—Doxorubicin—ovarian cancer	0.000341	0.00106	CcSEcCtD
Iloperidone—Anaemia—Epirubicin—ovarian cancer	0.00034	0.00105	CcSEcCtD
Iloperidone—Agitation—Epirubicin—ovarian cancer	0.000338	0.00105	CcSEcCtD
Iloperidone—Rash—Paclitaxel—ovarian cancer	0.000331	0.00103	CcSEcCtD
Iloperidone—Dermatitis—Paclitaxel—ovarian cancer	0.000331	0.00103	CcSEcCtD
Iloperidone—Vertigo—Epirubicin—ovarian cancer	0.000331	0.00102	CcSEcCtD
Iloperidone—Leukopenia—Epirubicin—ovarian cancer	0.00033	0.00102	CcSEcCtD
Iloperidone—Muscle spasms—Doxorubicin—ovarian cancer	0.000328	0.00101	CcSEcCtD
Iloperidone—Palpitations—Epirubicin—ovarian cancer	0.000325	0.00101	CcSEcCtD
Iloperidone—Vision blurred—Doxorubicin—ovarian cancer	0.000321	0.000995	CcSEcCtD
Iloperidone—Asthenia—Docetaxel—ovarian cancer	0.00032	0.00099	CcSEcCtD
Iloperidone—Anaemia—Doxorubicin—ovarian cancer	0.000315	0.000975	CcSEcCtD
Iloperidone—Myalgia—Epirubicin—ovarian cancer	0.000314	0.000971	CcSEcCtD
Iloperidone—Arthralgia—Epirubicin—ovarian cancer	0.000314	0.000971	CcSEcCtD
Iloperidone—Agitation—Doxorubicin—ovarian cancer	0.000313	0.00097	CcSEcCtD
Iloperidone—Nausea—Paclitaxel—ovarian cancer	0.000312	0.000967	CcSEcCtD
Iloperidone—Dry mouth—Epirubicin—ovarian cancer	0.000307	0.00095	CcSEcCtD
Iloperidone—Vertigo—Doxorubicin—ovarian cancer	0.000306	0.000948	CcSEcCtD
Iloperidone—Leukopenia—Doxorubicin—ovarian cancer	0.000305	0.000945	CcSEcCtD
Iloperidone—Diarrhoea—Docetaxel—ovarian cancer	0.000305	0.000944	CcSEcCtD
Iloperidone—Confusional state—Epirubicin—ovarian cancer	0.000303	0.000939	CcSEcCtD
Iloperidone—Palpitations—Doxorubicin—ovarian cancer	0.000301	0.000933	CcSEcCtD
Iloperidone—Oedema—Epirubicin—ovarian cancer	0.000301	0.000931	CcSEcCtD
Iloperidone—Infection—Epirubicin—ovarian cancer	0.000299	0.000925	CcSEcCtD
Iloperidone—Nervous system disorder—Epirubicin—ovarian cancer	0.000295	0.000913	CcSEcCtD
Iloperidone—Dizziness—Docetaxel—ovarian cancer	0.000295	0.000913	CcSEcCtD
Iloperidone—Tachycardia—Epirubicin—ovarian cancer	0.000293	0.000908	CcSEcCtD
Iloperidone—Myalgia—Doxorubicin—ovarian cancer	0.00029	0.000898	CcSEcCtD
Iloperidone—Arthralgia—Doxorubicin—ovarian cancer	0.00029	0.000898	CcSEcCtD
Iloperidone—Dry mouth—Doxorubicin—ovarian cancer	0.000284	0.000879	CcSEcCtD
Iloperidone—Rash—Docetaxel—ovarian cancer	0.000281	0.00087	CcSEcCtD
Iloperidone—Hypotension—Epirubicin—ovarian cancer	0.000281	0.00087	CcSEcCtD
Iloperidone—Dermatitis—Docetaxel—ovarian cancer	0.000281	0.000869	CcSEcCtD
Iloperidone—Confusional state—Doxorubicin—ovarian cancer	0.00028	0.000868	CcSEcCtD
Iloperidone—Oedema—Doxorubicin—ovarian cancer	0.000278	0.000861	CcSEcCtD
Iloperidone—Infection—Doxorubicin—ovarian cancer	0.000276	0.000856	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000274	0.000848	CcSEcCtD
Iloperidone—Nervous system disorder—Doxorubicin—ovarian cancer	0.000273	0.000845	CcSEcCtD
Iloperidone—Tachycardia—Doxorubicin—ovarian cancer	0.000271	0.000841	CcSEcCtD
Iloperidone—Paraesthesia—Epirubicin—ovarian cancer	0.00027	0.000836	CcSEcCtD
Iloperidone—Dyspnoea—Epirubicin—ovarian cancer	0.000268	0.00083	CcSEcCtD
Iloperidone—Somnolence—Epirubicin—ovarian cancer	0.000267	0.000828	CcSEcCtD
Iloperidone—Nausea—Docetaxel—ovarian cancer	0.000265	0.00082	CcSEcCtD
Iloperidone—Hypotension—Doxorubicin—ovarian cancer	0.00026	0.000805	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000259	0.000804	CcSEcCtD
Iloperidone—Fatigue—Epirubicin—ovarian cancer	0.000259	0.000803	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000253	0.000785	CcSEcCtD
Iloperidone—Paraesthesia—Doxorubicin—ovarian cancer	0.00025	0.000773	CcSEcCtD
Iloperidone—Dyspnoea—Doxorubicin—ovarian cancer	0.000248	0.000768	CcSEcCtD
Iloperidone—Feeling abnormal—Epirubicin—ovarian cancer	0.000248	0.000767	CcSEcCtD
Iloperidone—Somnolence—Doxorubicin—ovarian cancer	0.000247	0.000766	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00024	0.000744	CcSEcCtD
Iloperidone—Fatigue—Doxorubicin—ovarian cancer	0.00024	0.000743	CcSEcCtD
Iloperidone—Body temperature increased—Epirubicin—ovarian cancer	0.000238	0.000736	CcSEcCtD
Iloperidone—Feeling abnormal—Doxorubicin—ovarian cancer	0.000229	0.00071	CcSEcCtD
Iloperidone—Body temperature increased—Doxorubicin—ovarian cancer	0.00022	0.000681	CcSEcCtD
Iloperidone—Asthenia—Epirubicin—ovarian cancer	0.000216	0.000668	CcSEcCtD
Iloperidone—Diarrhoea—Epirubicin—ovarian cancer	0.000206	0.000637	CcSEcCtD
Iloperidone—Asthenia—Doxorubicin—ovarian cancer	0.0002	0.000618	CcSEcCtD
Iloperidone—Dizziness—Epirubicin—ovarian cancer	0.000199	0.000616	CcSEcCtD
Iloperidone—Diarrhoea—Doxorubicin—ovarian cancer	0.00019	0.000589	CcSEcCtD
Iloperidone—Rash—Epirubicin—ovarian cancer	0.000189	0.000587	CcSEcCtD
Iloperidone—Dermatitis—Epirubicin—ovarian cancer	0.000189	0.000586	CcSEcCtD
Iloperidone—Dizziness—Doxorubicin—ovarian cancer	0.000184	0.00057	CcSEcCtD
Iloperidone—Nausea—Epirubicin—ovarian cancer	0.000179	0.000553	CcSEcCtD
Iloperidone—Rash—Doxorubicin—ovarian cancer	0.000175	0.000543	CcSEcCtD
Iloperidone—Dermatitis—Doxorubicin—ovarian cancer	0.000175	0.000543	CcSEcCtD
Iloperidone—Nausea—Doxorubicin—ovarian cancer	0.000165	0.000512	CcSEcCtD
Iloperidone—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	3.37e-06	0.000136	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	3.37e-06	0.000136	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CXCL8—ovarian cancer	3.36e-06	0.000136	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	3.36e-06	0.000136	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	3.35e-06	0.000135	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	3.34e-06	0.000135	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—HRAS—ovarian cancer	3.34e-06	0.000135	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	3.33e-06	0.000135	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MYC—ovarian cancer	3.33e-06	0.000134	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	3.31e-06	0.000134	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CXCL8—ovarian cancer	3.3e-06	0.000133	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	3.29e-06	0.000133	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	3.28e-06	0.000133	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MYC—ovarian cancer	3.28e-06	0.000133	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—PIK3CA—ovarian cancer	3.28e-06	0.000133	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—HRAS—ovarian cancer	3.28e-06	0.000132	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—PIK3CA—ovarian cancer	3.28e-06	0.000132	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—PIK3CA—ovarian cancer	3.25e-06	0.000132	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MAPK1—ovarian cancer	3.25e-06	0.000132	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—EGFR—ovarian cancer	3.25e-06	0.000131	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	3.25e-06	0.000131	CbGpPWpGaD
Iloperidone—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	3.25e-06	0.000131	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	3.24e-06	0.000131	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PTEN—ovarian cancer	3.23e-06	0.000131	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	3.23e-06	0.000131	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	3.23e-06	0.000131	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	3.22e-06	0.00013	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	3.22e-06	0.00013	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CASP3—ovarian cancer	3.22e-06	0.00013	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL2—ovarian cancer	3.21e-06	0.00013	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MAPK1—ovarian cancer	3.21e-06	0.00013	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—EGFR—ovarian cancer	3.21e-06	0.00013	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—IL6—ovarian cancer	3.2e-06	0.000129	CbGpPWpGaD
Iloperidone—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	3.19e-06	0.000129	CbGpPWpGaD
Iloperidone—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	3.19e-06	0.000129	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CG—ovarian cancer	3.18e-06	0.000129	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TP53—ovarian cancer	3.17e-06	0.000128	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	3.17e-06	0.000128	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TP53—ovarian cancer	3.17e-06	0.000128	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CASP3—ovarian cancer	3.16e-06	0.000128	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	3.16e-06	0.000128	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL2—ovarian cancer	3.16e-06	0.000128	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CASP3—ovarian cancer	3.16e-06	0.000128	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL2—ovarian cancer	3.15e-06	0.000127	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TP53—ovarian cancer	3.15e-06	0.000127	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—IL6—ovarian cancer	3.14e-06	0.000127	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—IL6—ovarian cancer	3.14e-06	0.000127	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	3.14e-06	0.000127	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CCND1—ovarian cancer	3.13e-06	0.000127	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	3.13e-06	0.000127	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	3.13e-06	0.000127	CbGpPWpGaD
Iloperidone—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	3.13e-06	0.000126	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.11e-06	0.000126	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	3.11e-06	0.000126	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	3.1e-06	0.000125	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	3.1e-06	0.000125	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL2—ovarian cancer	3.09e-06	0.000125	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	3.09e-06	0.000125	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CCND1—ovarian cancer	3.08e-06	0.000124	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	3.08e-06	0.000124	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—STAT3—ovarian cancer	3.08e-06	0.000124	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CCND1—ovarian cancer	3.07e-06	0.000124	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—KRAS—ovarian cancer	3.07e-06	0.000124	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—NRAS—ovarian cancer	3.07e-06	0.000124	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—STAT3—ovarian cancer	3.06e-06	0.000124	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—NRAS—ovarian cancer	3.05e-06	0.000123	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	3.05e-06	0.000123	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	3.04e-06	0.000123	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MMP9—ovarian cancer	3.04e-06	0.000123	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—HRAS—ovarian cancer	3.03e-06	0.000123	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TP53—ovarian cancer	3.03e-06	0.000123	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—KRAS—ovarian cancer	3.03e-06	0.000123	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—HRAS—ovarian cancer	3.03e-06	0.000123	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PTEN—ovarian cancer	3.02e-06	0.000122	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	3.02e-06	0.000122	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—HRAS—ovarian cancer	3.01e-06	0.000122	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	3.01e-06	0.000122	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	3.01e-06	0.000122	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MMP9—ovarian cancer	2.99e-06	0.000121	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	2.99e-06	0.000121	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	2.99e-06	0.000121	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MMP9—ovarian cancer	2.98e-06	0.000121	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	2.98e-06	0.00012	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PTEN—ovarian cancer	2.97e-06	0.00012	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	2.97e-06	0.00012	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTEN—ovarian cancer	2.97e-06	0.00012	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PTEN—ovarian cancer	2.97e-06	0.00012	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTEN—ovarian cancer	2.96e-06	0.00012	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—CAV1—ovarian cancer	2.96e-06	0.00012	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—AKT1—ovarian cancer	2.95e-06	0.000119	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	2.94e-06	0.000119	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	2.94e-06	0.000119	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	2.93e-06	0.000118	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	2.93e-06	0.000118	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	2.91e-06	0.000118	CbGpPWpGaD
Iloperidone—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	2.91e-06	0.000117	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—IL6—ovarian cancer	2.9e-06	0.000117	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—HRAS—ovarian cancer	2.9e-06	0.000117	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—IL6—ovarian cancer	2.9e-06	0.000117	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	2.9e-06	0.000117	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—AKT1—ovarian cancer	2.89e-06	0.000117	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PIK3CA—ovarian cancer	2.89e-06	0.000117	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.89e-06	0.000117	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—IL6—ovarian cancer	2.88e-06	0.000116	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	2.88e-06	0.000116	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL2—ovarian cancer	2.87e-06	0.000116	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	2.86e-06	0.000116	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MYC—ovarian cancer	2.86e-06	0.000116	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	2.85e-06	0.000115	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MYC—ovarian cancer	2.85e-06	0.000115	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	2.84e-06	0.000115	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—TYMS—ovarian cancer	2.84e-06	0.000115	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.83e-06	0.000114	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	2.82e-06	0.000114	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PIK3CA—ovarian cancer	2.81e-06	0.000114	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	2.8e-06	0.000113	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.8e-06	0.000113	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	2.8e-06	0.000113	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—EGFR—ovarian cancer	2.8e-06	0.000113	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	2.79e-06	0.000113	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	2.78e-06	0.000112	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—EGFR—ovarian cancer	2.78e-06	0.000112	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—IL6—ovarian cancer	2.78e-06	0.000112	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	2.78e-06	0.000112	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MYC—ovarian cancer	2.77e-06	0.000112	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TP53—ovarian cancer	2.73e-06	0.00011	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—VEGFA—ovarian cancer	2.73e-06	0.00011	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	2.72e-06	0.00011	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	2.71e-06	0.000109	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	2.71e-06	0.000109	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	2.7e-06	0.000109	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—STAT3—ovarian cancer	2.7e-06	0.000109	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.7e-06	0.000109	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—NRAS—ovarian cancer	2.7e-06	0.000109	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TP53—ovarian cancer	2.7e-06	0.000109	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	2.69e-06	0.000109	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—VEGFA—ovarian cancer	2.68e-06	0.000108	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—AKT1—ovarian cancer	2.68e-06	0.000108	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—AKT1—ovarian cancer	2.68e-06	0.000108	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—AKT1—ovarian cancer	2.66e-06	0.000107	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—STAT3—ovarian cancer	2.66e-06	0.000107	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—STAT3—ovarian cancer	2.65e-06	0.000107	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—NRAS—ovarian cancer	2.65e-06	0.000107	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—NRAS—ovarian cancer	2.65e-06	0.000107	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—KRAS—ovarian cancer	2.64e-06	0.000107	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	2.64e-06	0.000107	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	2.63e-06	0.000106	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—KRAS—ovarian cancer	2.63e-06	0.000106	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—HRAS—ovarian cancer	2.61e-06	0.000106	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	2.6e-06	0.000105	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	2.6e-06	0.000105	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MAPK3—ovarian cancer	2.58e-06	0.000104	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—HRAS—ovarian cancer	2.58e-06	0.000104	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—AKT1—ovarian cancer	2.56e-06	0.000104	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	2.56e-06	0.000103	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	2.54e-06	0.000103	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MAPK3—ovarian cancer	2.53e-06	0.000102	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MYC—ovarian cancer	2.51e-06	0.000101	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—IL6—ovarian cancer	2.5e-06	0.000101	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	2.49e-06	0.000101	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MYC—ovarian cancer	2.47e-06	9.99e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—IL6—ovarian cancer	2.47e-06	9.97e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MYC—ovarian cancer	2.47e-06	9.96e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MAPK1—ovarian cancer	2.46e-06	9.93e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—EGFR—ovarian cancer	2.46e-06	9.93e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	2.44e-06	9.87e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CB—ovarian cancer	2.44e-06	9.86e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	2.43e-06	9.81e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MYC—ovarian cancer	2.42e-06	9.78e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	2.42e-06	9.78e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	2.42e-06	9.77e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—EGFR—ovarian cancer	2.42e-06	9.77e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	2.42e-06	9.76e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	2.41e-06	9.75e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MAPK1—ovarian cancer	2.41e-06	9.75e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—EGFR—ovarian cancer	2.41e-06	9.75e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CD—ovarian cancer	2.37e-06	9.58e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	2.37e-06	9.57e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	2.37e-06	9.56e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—AKT1—ovarian cancer	2.36e-06	9.55e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	2.35e-06	9.49e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TP53—ovarian cancer	2.35e-06	9.49e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TP53—ovarian cancer	2.34e-06	9.44e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—KRAS—ovarian cancer	2.32e-06	9.38e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	2.31e-06	9.34e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—AKT1—ovarian cancer	2.31e-06	9.32e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—AKT1—ovarian cancer	2.3e-06	9.28e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—CAV1—ovarian cancer	2.29e-06	9.24e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—KRAS—ovarian cancer	2.28e-06	9.23e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PIK3CA—ovarian cancer	2.28e-06	9.22e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—KRAS—ovarian cancer	2.28e-06	9.21e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—AKT1—ovarian cancer	2.28e-06	9.2e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TP53—ovarian cancer	2.27e-06	9.19e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MYC—ovarian cancer	2.25e-06	9.08e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—HRAS—ovarian cancer	2.25e-06	9.08e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	2.24e-06	9.03e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—HRAS—ovarian cancer	2.23e-06	9.03e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	2.2e-06	8.89e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	2.2e-06	8.89e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	2.17e-06	8.78e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL6—ovarian cancer	2.15e-06	8.69e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL6—ovarian cancer	2.14e-06	8.64e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	2.13e-06	8.62e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTEN—ovarian cancer	2.11e-06	8.52e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	2.1e-06	8.48e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PIK3CA—ovarian cancer	2.1e-06	8.47e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	2.09e-06	8.46e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PIK3CA—ovarian cancer	2.09e-06	8.45e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.08e-06	8.41e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL6—ovarian cancer	2.08e-06	8.41e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	2.08e-06	8.39e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CB—ovarian cancer	2.07e-06	8.35e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TP53—ovarian cancer	2.06e-06	8.33e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	2.05e-06	8.3e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TP53—ovarian cancer	2.03e-06	8.2e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TP53—ovarian cancer	2.02e-06	8.18e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TP53—ovarian cancer	1.99e-06	8.03e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—AKT1—ovarian cancer	1.98e-06	8.02e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—AKT1—ovarian cancer	1.97e-06	7.97e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—HRAS—ovarian cancer	1.97e-06	7.97e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—HRAS—ovarian cancer	1.94e-06	7.84e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—HRAS—ovarian cancer	1.94e-06	7.83e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	1.92e-06	7.76e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	1.91e-06	7.71e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	1.9e-06	7.68e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL6—ovarian cancer	1.89e-06	7.63e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—AKT1—ovarian cancer	1.86e-06	7.53e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL6—ovarian cancer	1.86e-06	7.51e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL6—ovarian cancer	1.85e-06	7.49e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TP53—ovarian cancer	1.85e-06	7.46e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.83e-06	7.4e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL6—ovarian cancer	1.82e-06	7.35e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTEN—ovarian cancer	1.79e-06	7.22e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	1.77e-06	7.14e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—AKT1—ovarian cancer	1.74e-06	7.04e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—AKT1—ovarian cancer	1.71e-06	6.93e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—AKT1—ovarian cancer	1.71e-06	6.92e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—AKT1—ovarian cancer	1.71e-06	6.91e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—AKT1—ovarian cancer	1.71e-06	6.9e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL6—ovarian cancer	1.69e-06	6.83e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	1.68e-06	6.78e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.59e-06	6.45e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	1.56e-06	6.3e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.49e-06	6.01e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTEN—ovarian cancer	1.38e-06	5.57e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.26e-06	5.09e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—AKT1—ovarian cancer	1.21e-06	4.91e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—AKT1—ovarian cancer	1.03e-06	4.16e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	9.72e-07	3.93e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—AKT1—ovarian cancer	7.94e-07	3.21e-05	CbGpPWpGaD
